(Rac) -Minzasolmin [CAS 1802518-63-3]

(Rac) -Minzasolmin ((Rac) -UCB0599; NPT200-11) is a blood-brain barrier penetrated alpha-synuclein (ASYN) misfolding inhibitor. (Rac) -Minzasolmin acts on the early stage of ASYN aggregation process, by replacing the membrane-bound oligomers ASYN, allowing them to revert to the monomeric form, while preventing pathological aggregation. (Rac) -Minzasolmin effectively improves the ASYN deposition in the retina and the neuro-pathological indicators in two α-synuclein transgenic mouse models. (Rac) -Minzasolmin can be used for the studies of Parkinson's disease (PD) and dementia with Lewy bodies (DLB) [1].

[1802518-63-3]

C23H31N5OS

425.59

O=C(C1=CN=C(N2CCN(CC2)C)S1)NC(CCCC)CC3=CNC4=CC=CC=C34

α-synuclein

α-synuclein Aggregation

99.87

DMSO : 100 mg/mL (ultrasonic)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature